JPWO2020006312A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006312A5 JPWO2020006312A5 JP2020571522A JP2020571522A JPWO2020006312A5 JP WO2020006312 A5 JPWO2020006312 A5 JP WO2020006312A5 JP 2020571522 A JP2020571522 A JP 2020571522A JP 2020571522 A JP2020571522 A JP 2020571522A JP WO2020006312 A5 JPWO2020006312 A5 JP WO2020006312A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- antigen
- pharmaceutical composition
- bifunctional compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 230000001588 bifunctional effect Effects 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 33
- 230000008685 targeting Effects 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 17
- 208000003174 Brain Neoplasms Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 5
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 5
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 5
- 101150013553 CD40 gene Proteins 0.000 claims 5
- 102100025221 CD70 antigen Human genes 0.000 claims 5
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 5
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 5
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 5
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 5
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 5
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 5
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 5
- 102100035721 Syndecan-1 Human genes 0.000 claims 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000006239 protecting group Chemical group 0.000 claims 5
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 4
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 4
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 4
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 4
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 4
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 4
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims 4
- 102100040120 Prominin-1 Human genes 0.000 claims 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- ASDLSKCKYGVMAI-UHFFFAOYSA-N 9,10-dioxoanthracene-2-carboxylic acid Chemical compound C1=CC=C2C(=O)C3=CC(C(=O)O)=CC=C3C(=O)C2=C1 ASDLSKCKYGVMAI-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010018852 Haematoma Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- -1 6-methylpyrazine-2-yl Chemical group 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000005620 boronic acid group Chemical group 0.000 claims 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015837A JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691486P | 2018-06-28 | 2018-06-28 | |
| US62/691,486 | 2018-06-28 | ||
| US201862697526P | 2018-07-13 | 2018-07-13 | |
| US62/697,526 | 2018-07-13 | ||
| PCT/US2019/039620 WO2020006312A1 (en) | 2018-06-28 | 2019-06-27 | Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015837A Division JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530444A JP2021530444A (ja) | 2021-11-11 |
| JPWO2020006312A5 true JPWO2020006312A5 (enExample) | 2022-07-04 |
Family
ID=68987577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571522A Pending JP2021530444A (ja) | 2018-06-28 | 2019-06-27 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
| JP2025015837A Pending JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015837A Pending JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12466869B2 (enExample) |
| EP (1) | EP3813863A4 (enExample) |
| JP (2) | JP2021530444A (enExample) |
| CN (1) | CN112399852A (enExample) |
| AU (1) | AU2019291882A1 (enExample) |
| WO (1) | WO2020006312A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11877988B2 (en) | 2019-10-15 | 2024-01-23 | Diverse Biotech, Inc. | Conjugate molecules |
| WO2021102142A1 (en) * | 2019-11-19 | 2021-05-27 | Oklahoma Medical Research Foundation | Okn-007 as a therapeutic agent |
| US20230414754A1 (en) * | 2020-11-05 | 2023-12-28 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Conditional control of universal car t cells through stimulus-reactive adaptors |
| AU2021397206A1 (en) * | 2020-12-08 | 2023-07-27 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| US11883499B2 (en) | 2022-02-01 | 2024-01-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
| US11660348B1 (en) | 2022-02-01 | 2023-05-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
| WO2025085511A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Washington | Systems and methods for polymer-mediated activation of engineered cells |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| JP2010207133A (ja) * | 2009-03-10 | 2010-09-24 | Sony Corp | 細胞分離方法 |
| AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| EP2651442B1 (en) | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| MX2015003959A (es) | 2012-10-02 | 2015-11-16 | Epitherapeutics Aps | Inhibidores de histona demetilasas. |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR102357968B1 (ko) * | 2013-10-15 | 2022-02-03 | 더 스크립스 리서치 인스티튜트 | 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
| WO2015168656A2 (en) * | 2014-05-02 | 2015-11-05 | Adheren Incorporated | Biological complexes and methods for using same |
| PL3597742T3 (pl) | 2014-10-09 | 2022-11-14 | Yamaguchi University | Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR |
| WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
| ES3012402T3 (en) * | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| WO2016168769A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| CN105504042A (zh) | 2016-02-04 | 2016-04-20 | 北京艺妙神州医疗科技有限公司 | 检测car-t细胞的捕获探针、该细胞含量的检测方法及应用 |
| CN108697798A (zh) * | 2016-02-16 | 2018-10-23 | 达纳-法伯癌症研究所有限公司 | 免疫疗法组合物及方法 |
| US20170274095A1 (en) | 2016-03-23 | 2017-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| ES3030503T3 (en) * | 2016-10-19 | 2025-06-30 | Scripps Research Inst | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| EP3583218B1 (en) | 2017-02-17 | 2025-04-16 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CN110545847A (zh) * | 2017-04-25 | 2019-12-06 | 达纳-法伯癌症研究所有限公司 | 用于肿瘤的靶向免疫疗法的组合物和方法 |
| CN108490174B (zh) | 2018-04-18 | 2022-06-24 | 上海尚珞生物医药科技有限公司 | 检测car-t细胞的方法及其应用 |
| CN108660113A (zh) | 2018-05-21 | 2018-10-16 | 杭州启澜生物医学技术有限公司 | 一种制备改良型car-t细胞的方法 |
-
2019
- 2019-06-27 JP JP2020571522A patent/JP2021530444A/ja active Pending
- 2019-06-27 US US17/254,472 patent/US12466869B2/en active Active
- 2019-06-27 CN CN201980043041.XA patent/CN112399852A/zh active Pending
- 2019-06-27 WO PCT/US2019/039620 patent/WO2020006312A1/en not_active Ceased
- 2019-06-27 EP EP19825236.3A patent/EP3813863A4/en active Pending
- 2019-06-27 AU AU2019291882A patent/AU2019291882A1/en not_active Abandoned
-
2025
- 2025-02-03 JP JP2025015837A patent/JP2025072462A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cho et al. | Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside | |
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| JP2020505433A5 (enExample) | ||
| JP2020535173A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| JP2008503476A5 (enExample) | ||
| EP3490553B1 (en) | Combination comprising an indolinone compound and its use in the treatment of lymphoma | |
| US11524009B2 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | |
| WO2016204193A1 (ja) | 抗がん剤 | |
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2022508935A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| JPWO2020006312A5 (enExample) | ||
| JP7479292B2 (ja) | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| Cabanillas | Non-Hodgkin's lymphoma: the old and the new | |
| JPWO2020160527A5 (enExample) | ||
| Fuchs et al. | Current strategies and new approaches in the treatment of Hodgkin’s lymphoma | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| JPWO2021263026A5 (enExample) | ||
| Friedrichs et al. | Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report | |
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| JP2006523664A5 (enExample) | ||
| CN105916517A (zh) | 用于治疗或缓解高龄或晚期癌症患者的药物组合物 | |
| WO2012076688A1 (en) | Combination comprising a derivative of the family of the combretastatins and cetuximab |